FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-028
Estimated average burden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ULLIAN ELAINE</u>						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
						MA[VRTX]										X	X Director			10% C	wner
(Last)	_ast) (First) (Middle)				1111	int ( MA )											Office belov	er (give title v)		Other (specify below)	
C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 11/28/2005															
130 WAVERLY STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)																	Form filed by One Reporting Person				
CAMBRIDGE MA 02139																X	Form	Form filed by More than One Reporting			
(City)	(5	itate) (	(Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						ar)   Ē	xecution	Deemed ecution Date, any onth/Day/Year)		Transaction Disposed Code (Instr. 5)			ties Acquired (A) I Of (D) (Instr. 3, 4			4 and Secu Bene Own		cially d Following	6. Own Form: (D) or I (I) (Inst	Direct ndirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									С	Code	v	Amount		(A) or (D)	Price	Price		Reported Transaction(s) (Instr. 3 and 4)			(111501.4)
Common Stock 11/28/						2005				S		600		D	\$25	.39	39 0		]	)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	Date,		ransaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Exe piration onth/Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		f g			9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dire or I (I) (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date	te ercisabl		Expiration Date	Titl	OI No Of	umber						

Explanation of Responses:

Remarks:

<u>Valerie L. Andrews, Attorney-</u> <u>In-Fact</u> <u>11/29/2005</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.